Latest News | Zydus Lifesciences Gets USFDA Nod for Generic Tavaborole Topical Solution

New Delhi, Apr 11 (PTI) Zydus Lifesciences Ltd on Tuesday said it has received final approval from the US health regulator for its generic Tavaborole topical solution indicated to treat fungal toenail infections.

The approval granted by the US Food and Drug Administration (USFDA) is to manufacture and market Tavaborole topical solution of strength 5 per cent, the company said in a regulatory filing.

Also Read | India Will Become Third Largest Economy in the World, Says Union Minister Mahendra Nath Pandey.

Tavaborole topical solution is indicated to treat fungal toenail infections that may cause nail discoloration, splitting, or pain.

The drug will be manufactured at the group's topical manufacturing facility at Changodar in Ahmedabad, it added.

Also Read | EV Sale: Electric Two-Wheeler Sales in India Rise Over Two-and-Half Fold to 8,46,976 Units in 2022-23.

The company said Tavaborole topical solution, 5 per cent, had annual sales of USD 3.1 million in the US citing IQVIA MAT February 2023 data.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)